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Abstract
Background: Although Ethiopia ranks seventh among the world’s 22 high-burden tuberculosis (TB) countries, little
is known about strain diversity and transmission. In this study, we present the first in-depth analysis of the
population structure and transmission dynamics of Mycobacterium tuberculosis strains from Northwest Ethiopia.
Methods: In the present study, 244 M. tuberculosis isolates where analysed by mycobacterial interspersed repetitive
unit - variable number tandem repeat 24-loci typing and spoligotyping methods to determine phylogenetic
lineages and perform cluster analysis. Clusters of strains with identical genotyping patterns were considered as an
indicator for the recent transmission.
Results: Of 244 isolates, 59.0% were classified into nine previously described lineages: Dehli/CAS (38.9%), Haarlem
(8.6%), Ural (3.3%), LAM (3.3%), TUR (2.0%), X-type (1.2%), S-type (0.8%), Beijing (0.4%) and Uganda II (0.4%).
Interestingly, 31.6% of the strains were grouped into four new lineages and were named as Ethiopia_3 (13.1%),
Ethiopia_1 (7.8%), Ethiopia_H37Rv like (7.0%) and Ethiopia_2 (3.7%) lineages. The remaining 9.4% of the isolates
could not be assigned to the known or new lineages. Overall, 45.1% of the isolates were grouped in clusters,
indicating a high rate of recent transmission.
Conclusions: This study confirms a highly diverse M. tuberculosis population structure, the presence of new
phylogenetic lineages and a predominance of the Dehli/CAS lineage in Northwest Ethiopia. The high rate of recent
transmission indicates defects of the TB control program in Northwest Ethiopia. This emphasizes the importance of
strengthening laboratory diagnosis of TB, intensified case finding and treatment of TB patients to interrupt the
chain of transmission.
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Background
Despite the existence of anti-tuberculosis drugs for the
last 60 years, tuberculosis (TB) continues to be a major
threat worldwide. In 2009, WHO estimated the global
incidence of TB with 9.4 million cases. Most of the
estimated number of TB cases occurred in Asia (55%)
and Africa (30%). The 22 high burden tuberculosis coun-
tries account for 81% of all estimated cases worldwide
[1]. Ethiopia ranks seventh among the world’s 22 high-
burden tuberculosis countries. The country had 314,267
TB cases in 2007, with an estimated incidence rate of
378 cases per 100,000 population [2]. According to the
Ministry of Health hospital statistics data, tuberculosis is
one of the leading causes of morbidity, the fourth most
common cause of hospital admission, and the second
most common cause of hospital death in Ethiopia [3].
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Additionally, the countrywide anti-TB drug resistance
survey conducted in 2005 showed that the prevalence of
multidrug resistant TB (MDR, resistance to at least iso-
niazid [INH] and rifampicin [RMP]) was 1.6% and 11.8%
among new cases and previously treated TB cases, re-
spectively [4]. These data show that the TB epidemic is a
significant public health threat in Ethiopia.
Molecular strain typing (genotyping) has contributed
significantly to the understanding of TB epidemiology
and has helped to improve TB control by providing in-
formation on transmission dynamics [5], determining
the importance of reactivation versus exogenous reinfec-
tion [6], investigating/confirming outbreaks [7], confirm-
ation of laboratory cross contamination [8] and to
identify the clonal spread of successful clones, including
multi-drug-resistant ones [9]. Furthermore, molecular
typing has revealed that the MTBC has a diverse popula-
tion structure with manifold lineages that show large dif-
ferences in their geographical occurrence and, also, in
their pathobiological properties e.g. development and
spread of drug resistance [10].
In Ethiopia, few molecular epidemiological studies
have been done so far only in the capital city, Addis
Ababa [11-13]. Recent data are only available from an
MDR strain targeted study from year 2006. However, the
strains were investigated by spoligotyping only, allowing
neither for high resolution phylogenetic strain classifica-
tion nor for analysis of transmission dynamics [11].
In this study, we used a combination of mycobacterial in-
terspersed repetitive unit-variable number tandem repeat
(MIRU-VNTR) typing and spoligotyping methods to inves-
tigate a large collection of MTBC strains isolated from pa-
tients living in Amhara region, Northwest Ethiopia. In
contrast to classical molecular typing methods such as
IS6110 DNA fingerprint and spoligotyping, 24-loci MIRU-
VNTR genotyping allows for a high-resolution discrimin-
ation of isolates for epidemiological studies and a valid
phylogenetic strain classification [14]. The data obtained
allow for new insights into population structure and trans-
mission dynamics, thus also revealing urgently needed data
to improve TB control in Ethiopia.
Methods
Study design, area and study period
A total of 260 smear positive pulmonary tuberculosis
patients diagnosed at Gondar Hospital, Gondar Health
Center, Metemma Hospital, Bahir Dar Hospital and Debre
Markos Hospital between March 2009 and July 2009 were
included in this study. For all study subjects, information
on the socio-demographic data, history of previous tuber-
culosis treatment, HIV status and the drug susceptibility
patterns of the M. tuberculosis isolates was available. The
single morning sputum sample and 5 ml venous blood
sample were collected prior to commencing TB treatment.
A structured questionnaire was used to classify patients
into new and previously treated tuberculosis cases and
to collect socio-demographic data of the study subjects.
Specimens were stored and transported to the Institute
of Medical Microbiology and Epidemiology of Infectious
Diseases, University Hospital of Leipzig, Germany as
described previously [15] for culture and drug suscepti-
bility testing. The study was approved by the research
and publication committee of University of Gondar,
Ethiopia. Written informed consent was obtained from
all study subjects.
Culture and drug susceptibility testing (DST)
Isolation, identification and DST were performed as de-
scribed previously [16]. Briefly, specimens were processed
and cultured according to the Deutsches Institut für
Normung (DIN) recommendations [17] using Lowenstein
Jensen (L-J) media, Gottsacker media and the BacT/ALERT
3D system. Isolates were identified by DNA hybridization
technology (GenoTypeW MTBC; Hain Lifescience, Nehren,
Germany) following the manufacturer’s instructions. DST for
first line drugs including isoniazid, rifampicin, streptomycin,
ethambutol and pyrazinamide was performed by BacT/
ALERT 3D system (BioMerieux, S.A, France) according to
the methods developed for MB/BacT system [18,19]. DST
for second line drugs including fluoroquinolones (FLQ)
(ofloxacin & moxifloxacin) and aminoglycocides (AM)/cyc-
lic peptides (CM) (capreomycin, viomicin/kanamycin and
amikacin) was performed using DNA hybridization tech-
nology on nitrocellulose strips (GenoTypeW MTBDRsl;
Hain Lifescience, Nehren, Germany) following the manu-
facturer’s instructions. Patients’ serum samples were
screened for HIV-1 and HIV-2 using Vironostika HIV Uni-
Form II Ag/Ab enzyme-linked immunosorbent assay
(ELISA) kit (Bio-Merieux, Boxtel, The Netherlands) follow-
ing the manufacturer’s instructions.
DNA extraction
DNA was extracted from all isolates by heating myco-
bacterial pellets obtained from liquid culture, suspended
in 200 μL 10 mM Tris–HCl, 1 mM EDTA (pH 7.0) buf-
fer at 95°C for 20 minutes followed by 15 minutes sonic-
ation in a sonicating water bath. The suspension was
centrifuged at 15,000 rpm for 1 minute, and the super-
natant was stored at -20°C until used.
Genotyping
All isolates were analyzed by spoligotyping technique as
described previously [20] and by 24 - loci MIRU-VNTR
genotyping technique as described previously [14].
Briefly, for MIRU-VNTR genotyping, 24 loci were ampli-
fied by using the MIRU-VNTR typing kit (Genoscreen,
Lille, France). Analyses of the PCR products were
performed by using the Rox-labeled MapMarker 1,500
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Table 1 Demographic characteristics of the study subjects, drug resistance patterns, phylogenetic lineages and their
association with strain clustering
Characteristics Genotyping patterns OR (95% CI) p-value
Clustered Unique
Gender
Male 63 79 0.9 (0.6-1.6) 0.791
Female 47 55 1
Age group (years)
≤ 45 93 117 0.8 (0.4-1.6) 0.534
>45 17 17 1
Address
Rural 52 60 1.1 (0.7-1.8) 0.697
Urban 58 74 1
Religion
Christian 108 130 1.7(0.3-9.2) 0.693*
Muslim 2 4 1
Previous TB treatment
Yes 26 17 2.1(1.1-4.2) 0.026
No 84 117 1
HIV status
Positive 24 38 0.7 (0.4-1.3) 0.243
Negative 86 96 1
Isoniazid
Resistant 22 12 2.5 (1.2-5.4) 0.013
Sensitive 88 122 1
Rifampicin
Resistant 9 5 2.3 (0.7-7.1) 0.137
Sensitive 101 129 1
Streptomycin
Resistant 19 7 3.8(1.5-9.4) 0.002
Sensitive 91 127 1
Ethambutol
Resistant 14 4 4.7 (1.5-14.9) 0.004
Sensitive 96 130 1
Pyrazinamid
Resistant 8 4 2.5(0.7-8.7) 0.123
Sensitive 102 130 1
Resistant to one or more FLD
Resistant 25 15 2.3(1.2-4.7) 0.015
Sensitive 85 119 1
MDR-TB
Yes 8 4 2.5(0.7-8.7) 0.123
No 102 130 1
Resistant to all FLD
Yes 8 1 10.4 (1.3-84.7) 0.012*
No 102 133 1
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size standard (BioVentures, Inc., Murfreesboro, VT) for
mix 5 and 1000 size standard (BioVentures, Inc.,
Murfreesboro, VT) for other mixes (mix 1–4, and mix
6–8), and using the ABI 3130 XL sequencer with 16 ca-
pillaries (Applied Biosystems, Foster City, CA). Sizing of
the PCR fragments and assignment of the various VNTR
alleles were done by using the GeneMapper software
version 4.0 (Applied Biosystems, Foster City, CA).
The MIRU-VNTR 24-loci profiles and spoligotyping
patterns were used to classify the strains into main
phylogenetic lineages by using the reference strain col-
lection and identification tools available online at www.
miru-vntrplus.org [21]. Briefly, a stepwise identification
procedure was carried out as follows. The strains were
first classified by the simple match approach that is
based on the best match with strains of the reference
database. The cut of distance for lineage assignment was
set to 0.17. In a second step, phylogenetic tree identifica-
tion was carried out. Additionally, for each MIRU-
VNTR 24-loci pattern a unique MLVA 15–9 code was
assigned by using the MIRU-VNTRplus nomenclature.
Cluster analyses of molecular typing data were per-
formed with the Bionumerics software (version 6.6;
Applied Maths, Sint-Martens-Latem, Belgium) according
to the manufacturers’ instructions. Similarities of geno-
typing patterns among strains were calculated by using
the categorical coefficient. A dendrogram was generated
by using the unweighted pair group method with arith-
metic averages (UPGMA). Minimum spanning tree ana-
lysis was done based on MIRU-VNTR typing data by
using the categorical coefficient. For the cluster analysis,
a cluster was defined as a minimum of two strains
harbouring identical DNA genotyping patterns (using
composite data, MIRU-VNTR 24-loci and spoligotyping)
from different patients belonging to the study subjects.
The recent transmission index (RTI) was calculated as
(number of clustered patients - number of clusters)/total
number of patients. Determination of the discriminatory
power of the genotyping methods (MIRU-VNTR 24-loci
typing and Spoligotyping) was calculated using the
Hunter-Gaston Discriminatory Index (HGDI) as previ-
ously described [22].
Statistical analysis
All laboratory data were entered, cleared and analyzed
using SPSS version 13 statistical package software (SPSS
Inc., Chicago, IL). Categorical data were compared by
the chi-square test or the fisher exact test, when
expected cell sizes (n) were smaller than 5. Two models
were constructed in a logistic regression analysis using
clusters and anti-TB drug resistance as the respective
outcome variables. In order to determine independent
risk factors, odds ratios (OR) and 95% confidence inter-
vals (CI) were calculated by using logistic regression
analysis for demographic (gender, age, address and reli-
gion), epidemiologic (previous treatment and HIV sta-
tus), and microbiological variables (drug resistance, and
infection by M. tuberculosis lineages). P-values less than
0.05 were considered statistically significant.
Table 1 Demographic characteristics of the study subjects, drug resistance patterns, phylogenetic lineages and their
association with strain clustering (Continued)
M. tuberculosis lineages
Dehli/CAS 51 44 6.2 (1.7-22.6) 0.006
Ethiopia_3 23 9 13.6(3.2-58.3) <0.001
Haarlem 9 12 4.0(0.9-18.0) 0.071
Ethiopia_1§ 3 16 1 -
Ethiopia_H37Rv like 9 8 6.0 (1.3-28.5) 0.024
Ethiopia_2 4 5 4.3 (0.7-25.9) 0.115
URAL 0 8 - -
LAM 3 5 3.2(0.5-21.2) 0.228
TUR 4 1 21.3(1.7- 263.7) 0.017
X-type 0 3 - -
S-type 0 2 - -
Beijing 0 1 - -
UgandII 0 1 - -
Not defined 4 19 1.1(0.2-5.8) 0.890
Total 110 (45.1) 134 (54.9) - -
*=Fisher exact test, FLD= First line anti-TB drugs, MDR= Multidrug resistant, §= reference category, LAM= M. tuberculosis Latin American Mediterranean.




A total of 260 M. tuberculosis isolates were utilized to
carry out MIRU-VNTR 24-loci and spoligotyping ana-
lysis. Out of these, 16 isolates were excluded from the
final analysis as for 15 of these, no PCR amplicon was
obtained at two or more loci and one multidrug resistant
isolate was identified as a mixture of two independent
strains during MIRU-VNTR typing. An occasional lack
of PCR amplification of some loci has been reported in a
previous study [14]. This might be explained by chromo-
somal deletion, nucleotide polymorphisms in the sequences
complementary to PCR primers [23], or insufficient DNA
quality. A mixture of two independent strains was also de-
fined by the presence of double alleles at two or more loci
[14,24]. Isolates with no PCR amplicon at only one locus
were treated as missing data at the respective loci and in-
cluded into the analysis. These observations remained the
same even after repeated testing with freshly prepared ma-
terials. For the remaining 244 isolates, valid genotyping data
were obtained and used for further analyses.
Some demographic data of the study subjects and drug
susceptibility test results for the isolates used herein
were included in our previous report [16]. Briefly, the
mean age ± the standard deviation of 244 study subjects
was 31.6 ± 12.5 (range, 68 years), and 58.2% patients
were male. Nearly all patients, 98.8% were Amhara by
ethnicity, and 97.5% patients were Christian by religion.
Of all study subjects, 17.6% patients were previously
treated cases and 25.4% patients were HIV co-infected
(Table 1).
Population structure and cluster analysis
According to the phylogenetic classification of 244 M.
tuberculosis isolates, using both the MIRU-VNTR 24-
loci profiles and spoligotyping patterns, 144 (59.0%)
were classified into previously described lineages as fol-
lows: 95 (38.9%) strains were Dehli/CAS, 21 (8.6%)
Haarlem, 8 (3.3%) Ural, 8 (3.3%) LAM (Latin American
Mediterranean), 5 (2.0%) TUR, 3 (1.2%) X-type, 2 (0.8%)
S-type, 1 (0.4%) Beijing and 1 (0.4%) Uganda II lineage.
Interestingly, 77 (31.6%) of the isolates were appear to
Figure 1 Radial UPGMA tree based on the copy numbers of MIRU-VNTR 24-loci. The tree was calculated by using the MIRU-VNTRplus
website. Abbreviations: LAM=M. tuberculosis Latin American Mediterranean.
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form four previously undefined lineages, the largest of
which comprising 32 (13.1%) isolates was named
Ethiopia_3, followed by a branch with 19 (7.8%) isolates
and was named as Ethiopia_1, a third branch with 17
(7.0%) isolates that were closely related to the laboratory
strain H37Rv was named Ethiopia_H37Rv like, and the
fourth branch with 9 (3.7%) strains was named as
Ethiopia_2. The remaining 23 (9.4%) isolates could not
be assigned to a known phylogenetic lineage or a new
lineage (Figure 1, Table 1, and Additional file 1: Figure
S1). To confirm this strain classification, we calculated a
minimum-spanning tree (MST) based on the MIRU-
VNTR 24- loci data. The MST (Figure 2) confirmed
the classification according to UPGMA tree-based ana-
lysis (Figure 1) and by comparison with the MIRU-
VNTRplus reference database. All lineages suspected
from dendrogram-based analysis were also detected as
clonal complexes in the MST, including the newly de-
scribed lineages (Figure 2).
Cluster analysis based on a composite data of MIRU-
VNTR 24-loci profiles and spoligotyping patterns re-
vealed that 110 of the 244 strains (45.1%) shared a
genotyping pattern with at least one other isolate and
were grouped in 36 clusters ranging in size from 2 to 13
strains, resulting in a resent transmission index (RTI) of
30.3%. The remaining strains were discriminated into
134 unique genotypes (Table 2). Strains were also
assigned to MLVA MtbC15-9 types. The largest cluster
(n = 13; cluster 5: MLVA MtbC15-9 type 594–15) is
formed by the Ethiopia-3 lineage, followed by the second
largest clusters formed by strains of the Dehli/CAS
lineage (n = 8, cluster 19: MLVA MtbC15-9 type 1557–
32), indicating ongoing transmission of these strains.
Of 12 MDR strains, 8 (66.7%) were in 5 clusters; three
clusters contained exclusively 2 MDR strains each, indi-
cating successful transmission of MDR strains within the
community, one cluster contained one MDR strain and
one INH, EMB and STM resistant strain, and one clus-
ter contained one MDR, one INH and STM resistant
strain and three fully susceptible strains, indicating
transmission of INH resistant strains that later devel-
oped MDR.
Factors associated with strain clustering
When the clustering rates were stratified for strains of
different phylogenetic lineages, we observed striking
Figure 2 Minimum spanning tree based on the diversity of MIRU-VNTR 24-loci data. The different complexes identified are coloured
(maximum neighbour distance: four changes; minimum size: two MIRU-VNTR types) by the set of 24-loci among the 244 M. tuberculosis strains
analyzed. The size of each circle is proportional to the number of MIRU-VNTR types belonging to a particular complex. LAM=M. tuberculosis Latin
American Mediterranean.
Tessema et al. BMC Infectious Diseases 2013, 13:131 Page 6 of 11
http://www.biomedcentral.com/1471-2334/13/131
differences. The odds of clustering was 21-fold higher
among TUR lineage (4 out of 5 strains) (P=0.017), 14-
fold higher among Ethiopia_3 lineage (23 out of 32
strains) (P<0.001), 6-fold higher among Dehli/CAS lineage
(51 out of 95 strains) (P=0.006) and 6-fold higher
among Ethiopia_H37Rv like lineage (9 out of 17 strains)
(P= 0.024) compared to Ethiopia_1 linage (3 out of 19
strains) (Table 1).
The odds of clustering was also 2-fold higher among
strains from previously treated cases (26 out of 43
strains) (P=0.026) compared to strains from the new
cases, nearly 3-fold higher among INH resistant strains
(22 out of 34 strains) compared to INH susceptible
strains (P=0.013), nearly 4-fold higher among STM re-
sistant strains (19 out of 26 strains) (P=0.002) compared
to STM susceptible strains, and nearly 5-fold higher
among EMB resistant strains (14 out of 18 strains)
(P=0.004) compared to EMB susceptible strains. Add-
itionally, strains that were resistant to one or more first
line anti-TB drugs had 2-fold higher odds of clustering
(25 out of 40 strains) (P=0.015) compared to fully
susceptible strains, and strains that were resistant to all
first line anti-TB drugs had 10-fold higher odds of clus-
tering (8 out of 9 strains) (P=0.012) compared to strains
that were susceptible to at least one first line anti-TB
drugs. However, multidrug resistance was not a signifi-
cant risk factor for clustering (8 out of 12 strains) (P =
0.123) compared to non multidrug resistant strains
(Table 1).
Interestingly, more than 50% of MDR strains were
classified as the Haarlem lineage (Table 3). Although the
numbers are small, the risk of having multidrug resistance
was 22-fold higher among patients with a Haarlem strain
(P <0.001) compared to patients with the non Haarlem
strains and the odds of resistance to all first line anti TB-
drugs was 10-fold higher among patients with a Haarlem
strain (P=0.004) compared to patients with non Haarlem
strains. Similarly, significantly higher risk of resistance to
INH (P=0.017), RMP (P<0.001), STM (P=0.015), EMB
(P=0.002) or PZA (P=0.002) was observed among patients
with a Haarlem strains compared to patients with the non
Haarlem strains (Table 4).
Table 2 Discriminatory capacities of spoligotyping and MIRU-VNTR 24-loci, alone or in combination for M. tuberculosis
isolates from Ethiopia
Genotyping method No. of different
patterns









Spoligotyping 69 43 26 201 82.4 64.8 0.88
MIRU-VNTR 24-loci 161 124 37 120 49.2 34.0 0.97
MIRU-VNTR 24-loci + Spoligotyping 170 134 36 110 45.1 30.3 0.97
HGDI= Hunter-Gastone discriminatory index, highest degree for HGDI is 1 that shows highest discriminatory power of a method, RTI= Recent transmission index.




Anti-TB drugs resistance PT N
(%)
HIV +
N (%)INH N (%) RMP N (%) STM N (%) EMB N (%) PZA N (%) MDR N (%) RFLD N (%)
Dehli/CAS (95) 10(10.0) 3(3.3) 10(10.5) 7(7.4) 2 (2.1) 2 (2.1) 2 (2.1) 19 (20.0) 24(25.3)
Ethiopia_3 (32) 10(31.0) 3(9.4) 6(18.8) 5(15.6) 4 (12.5) 3(9.4) 3(9.4) 7(21.9) 4(12.5)
Haarlem (21) 7(33.33) 7(33.3) 6(28.6) 6(28.6) 5 (23.8) 7 (33.3) 4 (19.0) 2(9.5) 7(33.3)
Ethiopia_1 (19) 1 (5.3) 0 1(5.3) 0 1(5.3) 0 0 5 (26.3) 4(21.1)
Ethiopia_H37Rv like (17) 2(11.8) 0 1(5.9) 0 0 0 0 3(17.6) 6(35.3)
Ethiopia_2 (9) 0 0 0 0 0 0 0 1(11.1) 1(11.1)
URAL (8) 0 0 0 0 0 0 0 0 3 (37.5)
LAM (8) 0 0 0 0 0 0 0 0 2 (25.0)
TUR (5) 2 (40.0) 0 1(20.0) 0 0 0 0 1(20.0) 2 (40.0)
X-type (3) 1(33.3) 0 1(33.3) 0 0 0 0 0 2(66.7)
S-type (2) 0 0 0 0 0 0 0 0 0
Beijing (1) 0 0 0 0 0 0 0 0 0
UgandII (1) 0 0 0 0 0 0 0 0 0
Not defined (23) 1 (4.3) 1(4.3) 0 0 0 0 0 5(21.7) 7(30.4)
Total (244) 34 (13.9) 14(5.7) 26(10.7) 18 (7.4) 12 (4.9) 12 (4.9) 9(3.7) 43(17.6) 62(25.4)
N= number, RFLD= Resistant to all first line anti-TB drugs, MDR= Multidrug resistant, LAM= M. tuberculosis Latin American Mediterranean, PT= previously treated
cases, INH=isoniazid, RMP=rifampicin, STM= streptomycin, EMB= ethambutol, PZA= pyrazinamid, + = positive.
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Discussion
Recent advances in molecular strain typing such as the
development of 24-loci MIRU-VNTR typing provide a
powerful tool to analyze MTBC population structure
and transmission dynamics locally and on the global
level, which provides valuable information for the devel-
opment of effective tuberculosis control policy. In this
study, we present the first in-depth analysis of the popu-
lation structure of M. tuberculosis strains in Northwest
Ethiopia based on high-resolution MIRU-VNTR 24-loci
typing and spoligotyping. Our data confirm a highly di-
verse population structure that comprises, thirteen
phylogenetic lineages, four of which were not described
before. Furthermore, our data indicate a high rate of re-
cent transmission, of which the spread of resistant and
MDR strains is of special importance.
While homoplasy is a true phenomenon within the
evolution of TB, spoligotyping has been shown to pro-
vide invalid phylogenetic classifications by suggesting
homoplasy too often [25]. In the contrary, the MIRU-
VNTR 24-loci typing method applied in our study has
the advantage to allow for high-resolution genotyping
needed for molecular epidemiological studies and,
simultaneously, for valid phylogenetic strain classifica-
tion enabling screening for new phylogenetic lineages/
clonal complexes [14].
Using this method, 90.6% of the strains investigated
were classified into various M. tuberculosis complex line-
ages; of which, 58.9% were described before and 31.6%
were newly described in this study. We documented that
M. tuberculosis Dehli/CAS is the predominant phylogen-
etic lineage in Ethiopia, accounting for 39% of investi-
gated strains. Similarly, a previously published study
from the capital city of Ethiopia showed that 43.5% of
the strains were of the CAS lineage [11], and a study
from Sudan [26] also showed that M. tuberculosis Dehli/
CAS is the predominant lineage (49%) of investigated
strains. The Dehli/CAS lineage is essentially localized in
the Central Asia and Middle-East, more specifically in
India [27]. Two hypotheses could explain the presence
of high Dehli/CAS lineage in Ethiopia: (i) the large
Indian and Chinese communities in Ethiopia due to the
growing economic partnerships between Ethiopia and
the two Asian countries, India and China may have con-
tributed in the introduction of this lineage; or (ii) this
lineage could have emerged from Ethiopia and migrated
Table 4 M. tuberculosis Haarlem lineage and its association with anti-tuberculosis drug resistance
Drug resistance M. tuberculosis lineages OR (95% CI) P-value*
Haarlem (n) Non Haarlem (n)
Isoniazid
R 7 27 3.6 (1.3-9.8) 0.017
S 14 196 1
Rifampicin
R 7 7 15.4 (4.7-50.2) <0.001
S 14 216 1
Streptomycin
R 6 20 4.1 (1.4-11.6) 0.015
S 15 203 1
Ethambutol
R 6 12 7.0(2.3-21.4) 0.002
S 15 211 1
Pyrazinamid
R 5 7 9.6 (2.7-33.8) 0.002
S 16 216 1
MDR-TB
Yes 7 5 21.8 (6.1-77.5) <0.001
No 14 218 1
Resistant to all FLD
Yes 4 5 10.3 (2.5-41.8) 0.004
No 17 218 1
R = resistant, S = sensitive, n = number, * = Fisher exact test, FLD = First line anti-TB drugs, MDR-TB = multidrug resistant tuberculosis.
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through Asia, this hypothesis is in agreement with the
suggestion that East Africa is the origin of M. tubercu-
losis complex species [28].
Additionally, we confirmed the presence of previously
undefined phylogenetic lineages named as Ethiopia_3,
Ethiopia_1, Ethiopia_H37RV-like and Ethiopia_2 that
were clearly defined by tree based, as well as by mini-
mum spanning tree-based analysis. However, compari-
son with other studies is hampered by the fact that they
are mainly based on IS6110 DNA fingerprint and/or
spoligotyping analysis hindering a valid analysis of the
population structure and standardized comparisons based
on MIRU-VNTR nomenclature. Thus, the actual picture
of M. tuberculosis population diversity in African, high-
incidence settings is largely incomplete and needs a
systematic investigation with phylogenetic useful genotyp-
ing methods.
This study also showed a significant association be-
tween infection with strains of the Haarlem lineage and
multi-drug resistance, resistance to all first line anti-TB
drugs and resistance to each first line anti-TB drugs in-
cluding INH, RMP, STM, EMB and PZA. Similarly, a
previous study from Tunisia showed that the Haarlem
family genotype has a similar relationship with drug
resistance and rapid clonal expansion [29]. From TB-
control point of view, it is relevant to understand whether
specific genotype families are overrepresented among
drug-resistant cases and, in particular, if these resistant
strains are successfully transmitted within the community.
In this study, HIV infection was not significantly associ-
ated with resistance to anti-TB drugs. The high HIV
prevalence in the study subjects did not appear to be a sig-
nificant risk factor selectively driving drug resistance de-
velopment and transmission. This might be due to the
fact that HIV infection increases the susceptibility of the
population for both drug susceptible and drug resistant
M. tuberculosis strains.
Clustering is a marker for recent transmission [30-32].
By using degree of recent TB transmission in a study
population, one can estimate the efficacy of the TB con-
trol program [30]. Both high TB incidence and the
current drug-resistance rates in Ethiopia are indicative
of defects of the TB control program [2,4,16]. Supporting
this suggestion, we found a high rate of clustering, 45.1%
of the total strains investigated. This is in agreement with
the previous reports from the capital city of Ethiopia that
showed clustering rate of 41.2% [13] and 48.1% [12].
Even more important, we confirm an elevated clustering
rate in drug resistant strains in general as well as for MDR
strains. Similarly, there was a significant association be-
tween recent transmission and patients with the history of
previous TB treatment, infection with INH resistant
strains, STM resistant strains, EMB resistant strains,
strains resistant to one or more first line anti-TB drugs
and patients with strains resistant to all first line anti-TB
drugs. This might be due to the fact that, in Ethiopia there
is no culture and drug susceptibility testing facility for
routine diagnosis of drug resistance, thus, drug resistant-
TB is only diagnosed after prolonged treatment with first-
line anti-TB drugs and clinical recognition that treatment
has failed. Treatment of drug-resistant TB with standard
first line drugs, instead of a regimen designed according to
the resistance pattern has several potential adverse conse-
quences: patients remain on inadequate treatment longer,
increasing the risk of treatment failure or death; selection
of drug resistant strains and patients remain infectious,
promoting transmission to close contacts [33]. These data
indicate a successful transmission of drug resistant and
MDR strains in the community, a situation that needs to
be carefully monitored in the future to determine exten-
sive transmission of resistant strains early enough to avoid
more significant problems for TB control as already emi-
nent in several parts of Eastern Europe or South Africa
[34,35].
Interestingly, we present evidence of significant associ-
ation between recent transmission and the Dehli/CAS,
Ethiopia_3, TUR and Ethiopia_H37Rv like strain infec-
tions. Similarly, Gagneux et al. have recently proposed
that the major M. tuberculosis lineages have evolved so
as to become adapted to specific host genetic back-
grounds and are much more likely to transmit and cause
disease among patients of the same ethnicity [36].
Conclusion
In conclusion, our study confirms a highly diverse popula-
tion structure of M. tuberculosis, the presence of phylo-
genetic lineages that were not described before and a
predominance of the Dehli/CAS lineage in the Amhara
region, Northwest Ethiopia. Our study also showed a sig-
nificant association between Haarlem strain infection and
resistance to first line anti-TB drugs including multidrug
reissuance. The high rate of recent transmission under-
lines active transmission of M. tuberculosis including
drug-resistant strains, and consequently the inefficacy of
TB control program in the study area. This emphasizes
the importance of strengthening laboratory diagnosis of
TB including culture and drug susceptibility testing, inten-
sified case finding and treatment of TB patients according
to the ongoing DOTS program to interrupt the chain of
transmission within the community. The continued devel-
opment of new high-resolution methodologies (eg. whole
genome sequencing) is still crucial.
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